Tempus AI, Inc.

NASDAQ:TEM

Medical - Healthcare Information Services

Healthcare
$63.62 -3.50%

-$1.77 today

Market cap
$11.28B
Beta
3.62
P/E (TTM)
-28.8
EPS (TTM)
-$1.69
52W Low $41.73High $104.32

Volume 5.35M

Average 6.17M

TEM Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Tempus AI, Inc.NASDAQ: TEM

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development dips below year-ago levels

Q3 FY2026 research & development of $45.71M fell 45.0% year over year, behind the +12.8% change in trailing-twelve-month research & development. Sequentially, it fell 52.7% from the prior quarter. Over 3 fiscal years it compounded at +25.3% a year.

Context

  • Research & development amounted to 25.1% of revenue in FY2025, down 20.6 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -45.0% toward the trailing-twelve-month pace of +12.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$45.71M-52.7% QoQ
Last fiscal yearDec 2025
$319.03M+0.7% YoY
LTMSep 2026
$327.05M+12.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-45.0%——
1 year+0.7%——
3-year CAGR+25.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
319.03M USD
Year-over-year change
+0.7%
4-year CAGR
+25.6%

Research & Development vs competitors

How TEM compares with its peers on the latest reported figures

  • TEM's LTM Sep 2026 research & development of $327.05M is the 4th highest of the 11 companies compared; the peer median is $82.81M.
  • Its year-over-year change of +12.8% is the 4th highest of 10, against a peer median of +7.6%.
  • Research & development amounts to 21.7% of revenue for TEM, versus a peer median of 13.9%.
TEM Competitors Peer median
Research & Development for TEM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ILMNIllumina, Inc.LTM Jun 2026$958M -3.4%-10.4%21.3%
NTRANatera, Inc.LTM Jun 2026$787.38M +56.9%+25.4%29.1%
GHGuardant Health, Inc.LTM Sep 2026$386.67M +7.6%-0.9%30.2%
TEMTempus AI, Inc.LTM Sep 2026$327.05M +12.8%+25.3%21.7%
QGENQiagen N.V.LTM Jun 2026$194.67M +5.5%-0.4%9.3%
MYGNMyriad Genetics, Inc.LTM Mar 2026$106.4M -7.7%+7.7%12.8%
BLLNBillionToOne, Inc.LTM Jun 2026$59.21M +38.6%—14.9%
PSNLPersonalis, Inc.LTM Mar 2026$52.16M +6.9%-8.2%80.9%
NEONeoGenomics, Inc.LTM Jun 2026$38.17M +9.5%+6.9%5.0%
BDSXBiodesix, Inc.LTM Mar 2026$12.42M +19.5%-2.9%12.9%
DGXQuest Diagnostics IncorporatedLTM Sep 2026$0 ——0.0%
Peer median (excluding TEM) $82.81M+7.6%-0.6%13.9%

Competitors are the stored peer set for TEM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue257.85M320.67M531.82M693.4M1.27B
Cost of Revenue174.21M190.48M245.65M312.29M473.89M
Gross Profit83.64M130.19M286.18M381.11M797.9M
Gross Margin32.4%40.6%53.8%55.0%62.7%
Research & Development128.35M162.25M185.5M316.84M319.03M
Selling, General & Admin199M233.38M296.76M755.35M715.43M
Operating Expenses327.36M395.63M482.26M1.07B1.05B
Depreciation & Amortization23.88M30.41M33.33M37.25M102.32M
EBITDA(219.52M)(236.85M)(133.33M)(610.42M)(118.51M)
EBITDA Margin-85.1%-73.9%-25.1%-88.0%-9.3%
Operating Income(243.71M)(265.44M)(196.08M)(691.08M)(252.87M)
Operating Margin-94.5%-82.8%-36.9%-99.7%-19.9%
Interest Income623K3.03M7.6M11.08M12.63M
Interest Expense15.18M21.89M46.87M53.65M70.27M
Other Income / Expenses(15.48M)(24.3M)(17.75M)(14.46M)(43.84M)
Income Before Tax(259.19M)(289.75M)(213.83M)(705.54M)(296.71M)
Pre-Tax Margin-100.5%-90.4%-40.2%-101.8%-23.3%
Income Tax Expense066K288K266K(51.68M)
Net Income(259.19M)(289.81M)(214.12M)(705.81M)(245.03M)
Net Margin-100.5%-90.4%-40.3%-101.8%-19.3%
EPS (Basic)(1.75)(1.97)(1.73)(4.60)(1.41)
EPS (Diluted)(1.75)(1.97)(1.73)(4.60)(1.41)
Weighted Avg Shares169.88M169.88M154.17M162.12M174.26M
Weighted Avg Shares (Diluted)169.88M169.88M154.17M162.12M174.26M

Tempus AI, Inc.

NASDAQ:TEM

Intrinsic Alpha fair value

Locked

Current Price

$63.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.